Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | The use of allogeneic transplantation in the era of checkpoint blockade therapy in Hodgkin lymphoma

Alberto Mussetti, MD, The Catalan Institute of Oncology, Barcelona, Spain, talks on the use of allogeneic transplantation and immune checkpoint inhibitors (ICIs) in Hodgkin lymphoma (HL). ICIs are currently approved in patients who relapse following standard of care (SOC) chemotherapy followed by autologous transplantation and brentuximab vedotin. Recommendations for the use of subsequent allogeneic transplantation are unclear as ICIs are known to increase the risk of immunological complications including acute and chronic graft-versus-host disease (GvHD). Currently, it is recommended to wait five to six weeks between the last ICI administration and transplantation, as well as to use additional strategies to minimize the incidence of immunotoxicity. ICIs can also be used after patients relapse following allogeneic transplantation. In that setting, it is recommended to start with a reduced ICI dose and progressively increase it if the patient doesn’t develop immunological complications. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.